Combined Oral Contraceptives in Polycystic Ovary Syndrome - Indications and Cautions


BOZDAĞ G. , Yildiz B. O.

POLYCYSTIC OVARY SYNDROME: NOVEL INSIGHT INTO CAUSES AND THERAPY, vol.40, pp.115-127, 2013 (Journal Indexed in SCI) identifier

  • Publication Type: Article / Review
  • Volume: 40
  • Publication Date: 2013
  • Title of Journal : POLYCYSTIC OVARY SYNDROME: NOVEL INSIGHT INTO CAUSES AND THERAPY
  • Page Numbers: pp.115-127

Abstract

Combined oral contraceptive pills (OCPs) have been used in women with polycystic ovary syndrome (PCOS) for the treatment of menstrual disorders, acne and hirsutism. Despite years of their use and broad clinical experience, there are still ongoing doubts concerning their implications for the cardiovascular system and carbohydrate metabolism both in the general population and women with PCOS. In the general population, the risk of venous thromboembolism is reported to be increased. However, arterial thrombotic events seem to require concomitant risk factors to appear during administration of OCPs. In terms of carbohydrate metabolism, available data do not consistently suggest an increased risk of impaired glucose tolerance (IGT) or conversion of IGT to type 2 diabetes mellitus, in spite of some subtle fluctuations in glucose and insulin levels. In subgroup analyses of epidemiological studies in the general population, there is no finding indicating an increased risk of cardiovascular disease and related mortality in premenopausal women with PCOS. There is no significant alteration in carbohydrate and lipid metabolism after use of OCP in PCOS either. The absence of further cardiometabolic risk with OCP use in PCOS might suggest some unproven preventive alterations in this patient population.